A phase I/II trial to evaluate the combination of infliximab and sorafenib in the treatment of renal cell carcinoma

Trial Profile

A phase I/II trial to evaluate the combination of infliximab and sorafenib in the treatment of renal cell carcinoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Infliximab (Primary) ; Sorafenib
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Aug 2017 Status changed from active, no longer recruiting to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 19 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top